Titan Pharmaceuticals (FRA:TN70) Operating Cash Flow per Share : €-7.04 (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals Operating Cash Flow per Share?

Titan Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2024 was €-0.66. Titan Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-7.04.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 53.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 63.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Titan Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

FRA:TN70' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -39 Med: 14 Max: 74.1
Current: 53

During the past 13 years, Titan Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.10% per year. The lowest was -39.00% per year. And the median was 14.00% per year.

FRA:TN70's 3-Year OCF Growth Rate is ranked better than
92.78% of 1233 companies
in the Biotechnology industry
Industry Median: 3.3 vs FRA:TN70: 53.00

Titan Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Titan Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Operating Cash Flow per Share Chart

Titan Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-365.82

-74.82

-14.36

-11.50

-8.65

Titan Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-2.36	-1.37	-2.29	-2.73	-0.66

Competitive Comparison of Titan Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Titan Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Titan Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Titan Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Titan Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-6.503	/	0.752
	=	-8.65

Titan Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-0.564	/	0.853
	=	-0.66

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.04

Titan Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (FRA:TN70) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

TTNP:USA

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines